RaySearch Laboratories AB Class B

As of June 30, 2026, RaySearch Laboratories AB Class B carries a market capitalization of 7.33B, placing it among publicly traded companies globally. Its enterprise value stands at 7.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

RaySearch Laboratories AB Class B's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, RaySearch Laboratories AB Class B has 33.62M shares outstanding.

As of June 30, 2026, RaySearch Laboratories AB Class B trades at a trailing price-to-earnings ratio of 35.07. The price-to-sales ratio is 5.88, and the price-to-book ratio stands at 9.30.

As of June 30, 2026, RaySearch Laboratories AB Class B trades at an EV/EBITDA multiple of 27.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. RaySearch Laboratories AB Class B trades at an EV/FCF ratio of 19.61, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.47B versus a market cap of 7.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, RaySearch Laboratories AB Class B maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, RaySearch Laboratories AB Class B posted a return on equity (ROE) of 26.02, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.19, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.56, useful for judging operating efficiency across full business cycles. The company generates approximately 2.98M in revenue per employee across its workforce of 426.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times RaySearch Laboratories AB Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, RaySearch Laboratories AB Class B recorded 58.30M in income tax expense. That works out to an effective tax rate of 21.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 270.80M, leaving 213.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, RaySearch Laboratories AB Class B's stock has declined approximately 16.68% over the past 52 weeks. The 50-day moving average sits at 182.45, while the 200-day moving average is 194.84.

Over the twelve months ended June 30, 2026, RaySearch Laboratories AB Class B generated 1.27B in revenue and converted that into 213.00M in net income, yielding earnings per share of 6.20. EBITDA reached 276.80M, while operating income came in at 276.70M.

As of June 30, 2026, RaySearch Laboratories AB Class B holds 213.10M in cash and equivalents against 359.20M in total debt, resulting in a net debt position of -213.10M. Total book value stands at 788.40M, with working capital of 179.60M providing operational flexibility.

RaySearch Laboratories AB Class B produced 411.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30.70M in capital expenditures, free cash flow totaled 381.10M - equivalent to 11.12 per share.

Over the twelve months ended June 30, 2026, RaySearch Laboratories AB Class B posted a gross margin of 93.03, reflecting its pricing power and cost economics. The operating margin of 21.78 and net profit margin of 16.77 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, RaySearch Laboratories AB Class B paid dividends of 4.00 per share. The dividend payout ratio of 64.52 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.86, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to RaySearch Laboratories AB Class B shareholders.

RaySearch Laboratories AB Class B's most recent stock split took place on June 25, 2008 with a 1:3 split ratio.